IONS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ionis Pharmaceuticals looks like a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to deploy. The stock is in a constructive trend, analyst sentiment is strongly positive with multiple recent target increases and fresh Buy/Overweight initiations, hedge funds are accumulating, and the options backdrop is supportive. At the current pre-market price of 77.33, the stock is still below most bullish analyst targets, so the risk/reward remains favorable for a long-term entry now rather than waiting.
IONS is showing a bullish short-term and medium-term setup. MACD histogram is positive and expanding, indicating strengthening momentum. The moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200), which typically signals an established uptrend. RSI_6 at 68.962 is near the upper range but not stretched enough to negate the trend. Price is trading near pivot resistance at 78.232, with support at 75.459 and deeper support at 72.685. The current structure suggests momentum remains intact and the stock is still in a favorable trend for long-term accumulation.
Hedge funds are also buying aggressively, with reported buying up 242.57% over the last quarter. The company appears to be benefiting from strong commercial momentum and pipeline optimism.
The main negatives are that RSI is near elevated levels and the stock is approaching near-term resistance around 78.23, which could limit immediate upside. There is also no confirmed AI Stock Picker or SwingMax signal today, so there is no proprietary momentum trigger to amplify conviction. The news flow provided is more focused on a competitor's hepatitis B progress than on direct Ionis-specific upside, so event-driven support is indirect rather than immediate.
Latest quarter information was not provided due to a financial snapshot error, so a full quarter-by-quarter assessment is limited. However, the analyst commentary indicates better-than-expected Q1 results and raised 2026 revenue guidance, which suggests improving growth trends. The latest quarter referenced in the notes is Q1 2026, and guidance revisions imply strengthening commercial execution and a positive revenue trajectory.
Analyst sentiment is clearly bullish and improving. Recent changes include Citi initiating Buy with a $115 target, Canaccord initiating Buy at $110, Morgan Stanley raising to $130, H.C. Wainwright to $125, Barclays to $115, RBC to $100, Oppenheimer to $111, and Stifel to $86. Only TD Cowen trimmed slightly to $108 while keeping Buy. Wall Street pros are generally constructive because they see underappreciated pipeline value, strong launches, and major upside from Tryngolza; the main con is that some of the more aggressive peak-sales assumptions may already be partly reflected in the share price.
